Browse hierarchy: [Cardiovascular (CV)](/submissions/CV) → [Subpart C — Cardiovascular Monitoring Devices](/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices) → [21 CFR 870.2380](/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/870.2380) → SAT — Pulmonary Hypertension Machine Learning-Based Notification Software

# SAT · Pulmonary Hypertension Machine Learning-Based Notification Software

_Cardiovascular · 21 CFR 870.2380 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/SAT

## Overview

- **Product Code:** SAT
- **Device Name:** Pulmonary Hypertension Machine Learning-Based Notification Software
- **Regulation:** [21 CFR 870.2380](/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/870.2380)
- **Device Class:** 2
- **Review Panel:** [Cardiovascular](/submissions/CV)

## Identification

Viz HCM is a cardiovascular machine learning-based notification software intended to be used in parallel to the standard of care to analyze 12-lead ECG recordings from patients 18 years of age or older. It detects signs associated with hypertrophic cardiomyopathy (HCM) and allows the user to view the ECG and analysis results. It is not intended for use on patients with implanted pacemakers, does not replace standard diagnostic methods, and is not intended to rule out HCM or be used in lieu of a full patient evaluation.

## Classification Rationale

Class II (special controls). The device is a cardiovascular machine learning-based notification software, regulated under 21 CFR 870.2380.

## Special Controls

In combination with the general controls of the FD&C Act, cardiovascular machine learningbased notification software is subject to the following special controls:

## Recent Cleared Devices (2 of 2)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K252360](https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/SAT/K252360.md) | ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020) | Anumana, Inc. | Mar 28, 2026 | SESE |
| [K233666](https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/SAT/K233666.md) | CorVista System with PH Add-On | Analytics For Life, Inc. | Apr 5, 2024 | SESE |

## Top Applicants

- Analytics For Life, Inc. — 1 clearance
- Anumana, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/SAT](https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/SAT)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com